ANTI-TUMOR ACTIONS OF PACLITAXEL PLUS CARBACOL ON HUMAN TRIPLE NEGATIVE BREAST CANCER CELLS

MARIA ELENA SALES; YAMILA SANCHEZ; AGUSTINA SALEM; ALEJANDRO ESPAÑOL

Buenos Aires

Congreso; LXII Reunión Anual de la Sociedad Argentina de Investigación Clínica (SAIC); 2017

SAIC-SAI-SAFE-SAFIS-SAIB-SAA-SAB-SAB-SHA-SAP.

Abstract: The administration of low doses of cytotoxic drugs alone or combined with repurposing drugs scheduled with short inter-dose intervals is called metronomic therapy (MT). MT is a new strategy in cancer treatment, since it exhibits high effectiveness and low incidence of side effects. The most aggressive type among human breast tumors is triple negative (TN), probably due to the absence of a specific target for pharmacological treatment. Here, we analyzed the effect of a combination of subthreshold concentrations of carbachol (CARB) (10-12M) with paclitaxel (PX) (10-8M) on MDA-MB231 cell line derived from a TN breast cancer patient during 40 h. By MTT assay we observed that the addition of 10-6M PX, a concentration similar to that used in conventional chemotherapy increased tumor cell death by 40±2% (p